Annual Drug Patent Expirations for IMBRUVICA
Imbruvica is a drug marketed by Pharmacyclics Inc and is included in three NDAs. It is available from one supplier. There are fifty-five patents protecting this drug and four Paragraph IV challenges.
Drug patent litigation for IMBRUVICA.
This drug has two hundred and ninety-one patent family members in forty-two countries.
The generic ingredient in IMBRUVICA is ibrutinib. One supplier is listed for this compound. Additional details are available on the ibrutinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
